ライフサイエンスコーパス: transurethral resection

1 ncer with particularly high recurrence after transurethral resection.

2 a safe, effective and durable alternative to transurethral resection.

3 Transurethral resection and instillation of perioperativ

4 carcinomas of the bladder were treated with transurethral resection and intravesical bacillus Calmet

5 rficial bladder cancer is still managed with transurethral resection and perioperative instillation o

6 patients who underwent either enucleation or transurethral resection as their initial treatment.

7 Transurethral resection biopsies of the prostatic urethr

8 e bladder cancer, combined-modality therapy (transurethral resection bladder tumor [TURBT], radiation

9 of those rendered T(1) at second look after transurethral resection bladder tumor, most still requir

10 than five cases in urologists, with previous transurethral resection experience.

11 Two to 4 weeks after complete transurethral resection, gemcitabine was administered in

12 Bipolar transurethral resection is a novel approach in treatment

13 nstillation of chemotherapeutic agents after transurethral resection is quickly becoming the standard

14 Despite current treatment after transurethral resection of a bladder tumor, recurrences

15 sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor, chemotherapy f

16 Concurrently performed transurethral resection of bladder tumor-TURP seems onco

17 All patients had transurethral resection of bladder tumour and twice-dail

18 Age (P =.78), race (P =.29), prior transurethral resection of prostate (P =.81), and treatm

19 as admitted with massive hematuria following transurethral resection of prostate for benign prostatic

20 of the procedures examined (P < .01, except transurethral resection of prostate, P = .76).

21 radiation delivered per treatment, and prior transurethral resection of prostate.

22 All patients underwent transurethral resection of the bladder (TURB) and had hi

23 Patients who received no LT, transurethral resection of the bladder tumor alone, or <

24 A transurethral resection of the bladder tumor and biopsy

25 ons and partial obstructions respond best to transurethral resection of the ejaculatory ducts (TURED)

26 rlson comorbidity score (P < .01), and prior transurethral resection of the prostate (OR, 1.65; P < .

27 state glands (> or = 60 cm3) or history of a transurethral resection of the prostate (TURP) as implan

28 Transurethral resection of the prostate (TURP) has long

29 with age, suggests that the frequent use of transurethral resection of the prostate (TURP) in recent

30 alised prostate cancer diagnosed by use of a transurethral resection of the prostate (TURP) in the UK

31 Eight percent of patients underwent a transurethral resection of the prostate (TURP) within 2

32 eks after radical prostatectomy (trial 1) or transurethral resection of the prostate (TURP; trial 2)

33 ent choice over the past 10 years, replacing transurethral resection of the prostate as the standard

34 on and catheter removal policy can result in transurethral resection of the prostate being performed

35 Optimizing each stage of transurethral resection of the prostate can result in re

36 rospective study of healthy men undergoing a transurethral resection of the prostate for benign prost

37 The new technique of bipolar transurethral resection of the prostate has been studied

38 ht to the market over the past decade or so, transurethral resection of the prostate has been undergo

39 At the same time, transurethral resection of the prostate has evolved into

40 i-centre studies in effectiveness of bipolar transurethral resection of the prostate is apparent.

41 the prostate are not as effective as either transurethral resection of the prostate or transurethral

42 sion of interest in surgical alternatives to transurethral resection of the prostate over the past de

43 In total, 156 prostate tissues from transurethral resection of the prostate procedures for b

44 Transurethral resection of the prostate remains a widely

45 Transurethral resection of the prostate remains the gold

46 Transurethral resection of the prostate remains the trea

47 Like many of the surgical alternatives to transurethral resection of the prostate this procedure s

48 sks the question of whether it will relegate transurethral resection of the prostate to an operation

49 -term results suggest equivalent efficacy to transurethral resection of the prostate with improved sa

50 agement was once limited to medical therapy, transurethral resection of the prostate, or open, relati

51 benign prostatic hyperplasia continues to be transurethral resection of the prostate, which is tradit

52 tatic outcomes compared to classic monopolar transurethral resection of the prostate.

53 dies have compared these two techniques with transurethral resection of the prostate.

54 tic hyperplasia was the electrocautery-based transurethral resection of the prostate.

55 tioned between pharmacological treatment and transurethral resection of the prostate.

56 e deemed high surgical risks for traditional transurethral resection of the prostate.

57 ajor advances that have occurred recently in transurethral resection of the prostate.

58 t challenge to the 'gold standard' status of transurethral resection of the prostate.

59 ggest there is no significant advantage over transurethral resection of the prostate.

60 etween June 2000 and July 2001 pertaining to transurethral resection of the prostate.

61 nt of superficial bladder cancer is based on transurethral resection of the tumor with perioperative

62 Both transurethral resection of the ureteral orifice (pluck)

63 f targeting of necrotic tissue from previous transurethral resections or chemotherapy are considered

64 RECENT FINDINGS: For improving transurethral resection quality, new optical enhancement

65 nd based on radical prostatectomy samples or transurethral resections rather than biopsy samples.

66 Transurethral resection remains the surgical mainstay fo

67 ime, a cystoscopy of his primary tumor and a transurethral resection revealed residual muscle-invasiv

68 itoring of irrigant absorption can eliminate transurethral resection syndrome.

69 Electrosurgical transurethral resection (TUR) of the prostate (TURP) has

70 Only randomized comparisons with transurethral resection will tell us if it is a worthy c

71 -sparing trimodality treatment consisting of transurethral resection with chemoradiation.

72 ients with high-risk NMIBC involves complete transurethral resection with intravesical BCG therapy.

73 ontinues to be managed predominantly through transurethral resection with perioperative instillation

74 mainstay of diagnosis remains cystoscopy and transurethral resection, with enhanced optical technique